doi: 10.1007/s11626-018-0310-2 240 ZhaoFDongJGuoJBiL
Use: Short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification, and caloric restriction in the management of exogenous obesity in patients with an initial body mass index (BMI) of 30 kg/m2 or greater, or BMI of 27 kg/m2 or greater in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia)
ask your clinician about short-term anti-nausea options if needed
Cardiovascular Disease or Uncontrolled Hypertension - There is insufficient research on the safety of PT-141, oxytocin, or tadalafil during pregnancy or lactation
ML226 was well tolerated up to 5 M, without affecting cell growth (Extended Data Fig
10.2147/DMSO.S54679 135 Novartis (2012)